ReviewAdvances in chronic kidney disease2010
Mass spectrometry in chronic kidney disease research.
Review in Advances in chronic kidney disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Emerging Urinary Biomarkers and Innovative Technologies for the Early Detection and Personalized Management of Chronic Kidney Disease.International journal of molecular sciences · 2026Review
- Proteogenomics in Nephrology: A New Frontier in Nephrological Research.Current issues in molecular biology · 2024Review
- Prognostic Significance of Amino Acid and Biogenic Amines Profiling in Chronic Kidney Disease.Biomedicines · 2023Article
- Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Assessment of uremic toxins in advanced chronic kidney disease patients on maintenance hemodialysis by LC-ESI-MS/MS.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- The systemic nature of CKD.Nature reviews. Nephrology · 2017Review
- Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.Diabetologia · 2016Review
- Can the Urinary Peptidome Outperform Creatinine and Albumin to Predict Renal Function Decline?Journal of the American Society of Nephrology : JASN · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Proteomics has evolved into an invaluable tool for biomedical research and for research on renal diseases. A central player in the proteomic revolution is the mass spectrometer and its application in analyzing biological samples. Our need to understand both the identity of proteins and their abundance has led to improvements in the ability of mass spectrometers (such as with the use of the LTQ-Orbitrap mass spectrometer) to analyze complex (tryptic) peptide mixtures with high sensitivity and high mass accuracy in a high-throughput manner. Unsurprisingly, this occurred coincidentally with dramatic improvements in our understanding of CKD, the mechanisms through which CKD progresses, and the development of candidate CKD biomarkers. This review attempts to present a basic framework for the operational components of mass spectrometers, basic insight into how they are used in renal research, and a discussion on CKD research related to mass spectrometry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.